Annual Secretarial Compliance Report for Year ended 31st March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sandu Pharmaceuticals has submitted its Annual Secretarial Compliance Report for FY 2025-26, certified by Practising Company Secretary Swapnil J. Dixit. The report examines compliance across multiple SEBI regulations including LODR, PIT, Depositories, and Takeover regulations. The company has complied with all applicable regulations during the review period. A prior-year non-compliance was noted: there was a delay in submitting financial results for FY 2024-25 under Regulation 33, which attracted a SEBI fine of Rs 30,000 plus 18% GST. The company has since paid this fine and remedied the default. No new additional non-compliances were observed during the current review period.
This is a routine compliance filing with no new red flags. The prior-year delay in financial result submission has been regularised. Shareholders can take comfort that the company is fully compliant with SEBI regulations for FY 2025-26, with no outstanding regulatory actions.